use of FDA oral polio formula in vaccinating Saudi children

ABSTRACT

To evaluate the immunogenicity of USA [FDA] Oral polio vaccine versus WHO Oral polio vaccine. Open randomized trial where 210 children were randomized into three groups. First group received Hemophilus influenza type b [Hib] vaccine plus WHO DTP and OPV. The second group received Hib plus FDA DTP and OPV. The third group received WHO DTP and OPV without Hib vaccine. 3 doses were given at 6 weeks, 3 months and 5 months. Blood samples were collected at 6 months of age. Bar coded sera were used to assess for polio antibody for the three poliovirus types using microneutralization assay. The result of polio assay will be presented in this paper. Proportion of children with detectable antibody [titre =/> 1/8] polioviruses were higher in the group vaccinated with the FDA OPV formula but no significant difference was found for our sample size. FDA oral polio is not superior to WHO OPV at our sample size and there is an improvement in the seroresponse to WHO OPV compared to previous survey